• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Efficacy of second-line chemotherapy after immunotherapy in advanced non-small cell lung cancer.免疫治疗后二线化疗在晚期非小细胞肺癌中的疗效
J Thorac Dis. 2023 Jul 31;15(7):3554-3556. doi: 10.21037/jtd-23-858. Epub 2023 Jul 10.
2
Efficacy and safety of first-line treatments with immune checkpoint inhibitors plus chemotherapy for non-squamous non-small cell lung cancer: a meta-analysis and indirect comparison.免疫检查点抑制剂联合化疗作为一线治疗非鳞状非小细胞肺癌的疗效和安全性：一项荟萃分析和间接比较。
Ann Palliat Med. 2021 Mar;10(3):2766-2775. doi: 10.21037/apm-20-1498. Epub 2021 Feb 1.
3
Immune checkpoint inhibitors beyond first-line progression with prior immunotherapy in patients with advanced non-small cell lung cancer.晚期非小细胞肺癌患者在一线进展后接受过免疫治疗的情况下使用免疫检查点抑制剂。
J Thorac Dis. 2023 Apr 28;15(4):1648-1657. doi: 10.21037/jtd-22-1611. Epub 2023 Mar 28.
4
Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.淋巴细胞亚群与晚期非小细胞肺癌免疫检查点抑制剂治疗疗效和预后的相关性：一项回顾性研究。
BMC Pulm Med. 2022 Apr 28;22(1):166. doi: 10.1186/s12890-022-01951-x.
5
Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review.免疫检查点抑制剂治疗非小细胞肺癌的成本效益：系统评价。
PLoS One. 2020 Sep 2;15(9):e0238536. doi: 10.1371/journal.pone.0238536. eCollection 2020.
6
Increased blood-based intratumor heterogeneity (bITH) is associated with unfavorable outcomes of immune checkpoint inhibitors plus chemotherapy in non-small cell lung cancer.肿瘤内血液异质性（bITH）增加与免疫检查点抑制剂联合化疗治疗非小细胞肺癌的不良结局相关。
BMC Med. 2022 Jul 29;20(1):256. doi: 10.1186/s12916-022-02444-8.
7
Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China.中国非小细胞肺癌一线治疗中的免疫疗法：现状与未来方向
Front Oncol. 2021 Nov 25;11:757993. doi: 10.3389/fonc.2021.757993. eCollection 2021.
8
Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer.化疗联合免疫检查点抑制剂与免疫检查点抑制剂单药治疗晚期和转移性非小细胞肺癌的比较。
Thorac Cancer. 2019 May;10(5):1158-1166. doi: 10.1111/1759-7714.13057. Epub 2019 Apr 5.
9
Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).非小细胞肺癌（NSCLC）中的免疫检查点抑制剂（ICIs）。
J UOEH. 2018;40(2):173-189. doi: 10.7888/juoeh.40.173.
10
Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.免疫检查点抑制剂在晚期非小细胞肺癌（NSCLC）患者中的疗效和安全性：一项系统文献综述。
Oncoimmunology. 2020 Jun 16;9(1):1774314. doi: 10.1080/2162402X.2020.1774314.

引用本文的文献

1
Response to platinum-based therapies in second-line after immunotherapy in advanced or metastatic non-small-cell lung cancer PD-L1 ≥50.在晚期或转移性非小细胞肺癌中，免疫治疗后二线铂类疗法对PD-L1≥50患者的疗效。
Transl Lung Cancer Res. 2024 Oct 31;13(10):2649-2659. doi: 10.21037/tlcr-24-513. Epub 2024 Oct 24.
2
Reinitiating Chemotherapy beyond Progression after Maintenance Immunotherapy in Extensive-Stage Small-Cell Lung Cancer.广泛期小细胞肺癌维持免疫治疗后进展后重新开始化疗。
Medicina (Kaunas). 2024 Jul 28;60(8):1225. doi: 10.3390/medicina60081225.

本文引用的文献

1
Analysis of real-world data to investigate evolving treatment sequencing patterns in advanced non-small cell lung cancers and their impact on survival.分析真实世界数据，以研究晚期非小细胞肺癌中不断演变的治疗顺序模式及其对生存的影响。
J Thorac Dis. 2023 May 30;15(5):2438-2449. doi: 10.21037/jtd-22-1481. Epub 2023 Apr 6.
2
Effect of prior immunotherapy on the efficacy of chemotherapy in advanced non-small cell lung cancer: A retrospective study.免疫治疗对晚期非小细胞肺癌化疗疗效的影响：一项回顾性研究。
Thorac Cancer. 2022 May;13(9):1391-1400. doi: 10.1111/1759-7714.14403. Epub 2022 Apr 17.
3
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.非小细胞肺癌患者一线纳武利尤单抗联合伊匹单抗加两个周期化疗（CheckMate 9LA）：一项国际、随机、开放标签、III 期临床试验。
Lancet Oncol. 2021 Feb;22(2):198-211. doi: 10.1016/S1470-2045(20)30641-0. Epub 2021 Jan 18.
4
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors.免疫检查点抑制剂时代的化疗免疫刺激。
Nat Rev Clin Oncol. 2020 Dec;17(12):725-741. doi: 10.1038/s41571-020-0413-z. Epub 2020 Aug 5.
5
Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L).非小细胞肺癌患者 PD-1 抑制剂治疗后与单纯化疗相比的倾向性评分加权分析（WJOG10217L）。
J Immunother Cancer. 2020 Feb;8(1). doi: 10.1136/jitc-2019-000350.
6
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial.纳武利尤单抗对比多西他赛用于经治的晚期 NSCLC 中国患者人群：CheckMate 078 随机 III 期临床研究。
J Thorac Oncol. 2019 May;14(5):867-875. doi: 10.1016/j.jtho.2019.01.006. Epub 2019 Jan 17.
7
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.阿替利珠单抗作为转移性非鳞状 NSCLC 一线治疗药物。
N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4.
8
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗治疗转移性非小细胞肺癌。
N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.
9
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.纳武利尤单抗联合伊匹单抗治疗高肿瘤突变负荷肺癌。
N Engl J Med. 2018 May 31;378(22):2093-2104. doi: 10.1056/NEJMoa1801946. Epub 2018 Apr 16.
10
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.阿特珠单抗对比多西他赛用于既往治疗过的非小细胞肺癌患者（OAK）：一项3期、开放标签、多中心随机对照试验
Lancet. 2017 Jan 21;389(10066):255-265. doi: 10.1016/S0140-6736(16)32517-X. Epub 2016 Dec 13.

Efficacy of second-line chemotherapy after immunotherapy in advanced non-small cell lung cancer.

作者信息

Hirata Tsuyoshi, Hakozaki Taiki

机构信息

Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.

Graduate School of Advanced Science and Engineering, Faculty of Science and Engineering, Waseda University, Tokyo, Japan.

出版信息

J Thorac Dis. 2023 Jul 31;15(7):3554-3556. doi: 10.21037/jtd-23-858. Epub 2023 Jul 10.

DOI:10.21037/jtd-23-858
PMID:37559596
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10407526/
Abstract
摘要